# SELSYM BIOTECH

**Revolutionizing hemorrhage control** 

#### Critical Unmet Need: Uncontrolled Bleeding in ER/Trauma and OR





#### Limitations of current hemorrhage control products

		Reliable supply?	Lack of off-target, immunologic, or burn/scarring risk?	Cost effective?	Ease of storage & transport?	Supports physiological clotting & healing?	Reactive & proactive hemostatic utility?
Products in use clinically	Platelets (Fresh or Processed)	×	$\mathbf{X}$	×	$\mathbf{x}$		
	PCC (Kcentra, Grifols)		×		$\mathbf{x}$		$\mathbf{X}$
	Factor VIIa (Novo Nordisk)		×		$\mathbf{x}$		$\mathbf{X}$
	Fibrin glue & topical thrombin (Tisseel, J&J Ethicon)					$\mathbf{x}$	$\mathbf{X}$
	QuikClot®		×			$\mathbf{x}$	$\mathbf{X}$
	SymClot						



### Our solution: SymClot

Synthetic platelets are shelf-stable and can be easily administered in the OR or at the point of traumatic injury





## SymClot:

Treatment modality allows for improved trauma management for civilian and military populations





# SymClot is safe and effective in "gold standard" hemorrhage models









Seema Nandi, PhD Co-Founder | CEO



L. Andrew Lyon, PhD Co-Founder | CSO



Ashley Brown, PhD Co-Founder | Sr. Scientific Advisor



Thomas Barker, PhD Co-Founder | President

SELSYM

BIOTECH



Heather Haworth, JD Board of Directors





- Director of Transfusion Services, Durham Veterans Affairs
- Clinical expertise: Transfusion medicine, Hematology



Kathleen Beach, MD, MPH Regulatory Strategy Advisor

 Former FDA Medical Officer, Center for Biologics Research & Evaluation (CBER)



- Nina Guzzetta, MD Clinical Advisory Board • Director,
- Director, Pediatric Cardiac Anesthesiology, Children's Hospital of Atlanta
- Clinical expertise: cardiac bypass procedures

Galen Robertson Business Advisor

CEO, VQ Biomedical Former COO, 410 Medical

